Should You Buy Astrana Health, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Astrana Health, Inc. (ASTH) occupies a solid middle-ground position with a Quality of Company score of 7.1/10. At the current market price of $38.35, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 2 of 9 CirclFi valuation models project upside for Astrana Health, Inc. (ASTH) at $38.35 — the model consensus leans bearish, with a Quality Score of 7.1/10 and Value-Trap risk of 64/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Astrana Health, Inc. (ASTH) in 2026?
What Is the Bull Case vs the Bear Case for Astrana Health, Inc. (ASTH)?
| Bull case — $64.30 target (+67.7%) | Bear case — $2.38 target (-93.8%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Astrana Health, Inc.'s score of 7.1/10 reflects durable competitive advantages that should sustain earnings power through market cycles. | According to the CirclFi Value Trap detector, Astrana Health, Inc. is flagged with elevated risk (Value Trap score of 64/100), suggesting that apparent cheapness may mask fundamental decay. |
| According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $64.30 (+67.7%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, the RCMH-DCF model sees the stock as overvalued with a fair value of $2.38 (-93.8%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +161.5% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
How Does ASTH Compare to Its Medical Care Facilities Peers?
Valuation data pages: AUNA · CYH · LFST · DCGO · JYNT · INNV · GBCS · FOXO · CHE · ADUS · NHC
Which Other Stocks Score Like ASTH on Quality?
Closest companies to ASTH’s Quality of Company score of 7.1/10, across all industries.
- EBS — Emergent BioSolutions Inc. (QOC 7.1) · analysis
- AOUT — American Outdoor Brands, Inc. (QOC 7.1) · analysis
- OSCR — Oscar Health, Inc. (QOC 7.1) · analysis
- ASAN — Asana, Inc. (QOC 7.1) · analysis
- MS — Morgan Stanley (QOC 7.1) · analysis
- SEDG — SolarEdge Technologies, Inc. (QOC 7.1) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Care Facilities Screens Does ASTH Appear In?
So Is Astrana Health, Inc. (ASTH) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on Astrana Health, Inc. at $38.35. 7/9 models flag overvaluation, median fair value sits at $23.81 (-37.9%), and value trap risk is elevated. Quality at 7.1/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. Astrana Health, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About ASTH Stock?
Should I buy ASTH stock right now?
Based on CirclFi's multi-model analysis, 2 of 9 models see upside for ASTH at $38.35. The models are divided, which means the investment case depends heavily on your assumptions about Astrana Health, Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Astrana Health, Inc.?
Key risks include: an elevated Value Trap score of 64/100, suggesting apparent undervaluation may mask deteriorating fundamentals; wide model disagreement (2598% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Care Facilities companies. Always diversify and consult a financial advisor.
How does ASTH compare to its competitors?
Among Medical Care Facilities peers, ASTH holds a Quality Score of 7.1/10. Comparable companies include AUNA (QOC 7.2), CYH (QOC 7.1), LFST (QOC 7.2). The relative ranking helps investors identify whether ASTH offers better fundamental quality than alternatives in the same sector.
Is ASTH a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ASTH's Quality Score of 7.1/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy ASTH at?
CirclFi does not provide target buy prices or price alerts. However, our 9 active models produce fair value estimates ranging from $2.38 to $64.30. At $38.35, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for ASTH.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad